Parkinson#8217;s disease (PD) is a progressive disorder of movement that affects over one million people in the US alone. There is currently no cure for PD and symptomatic drug therapy is the standard course, treating the symptoms of the disease but not necessarily slowing the rate of progression of the condition. Levodopa (L-dopa) has long been the mainstay of therapy for PD, but its long-term shortcomings #8211; principally unco-ordinated, spasmodic or irregular movements (dyskinesias) and fluctuating control of motor symptoms (#8216;on/off#8217; fluctuations) #8211; are well documented. This article discusses the current treatments for PD, as well as deal making and R&D trends.